OliX Pharmaceuticals Secured an Exclusive Right for OLX101A Development on Global Stage
NSP NEWS, By Hyun-jin Kim and Da-eun Kim
ENX7, Read 0
fullscreen(Seoul=NSP NEWS) = On 10 May, Olix Pharmaceuticals terminated the licensing agreement in Asia with Hugel for hypertrophic scar treatment, OLX101A.
The termination was due to a change in the internal policy of Hugel. The two companies agreed on returning the technology and license alike.
Therefore, Olix Pharmaceuticals becomes the only company with the exclusive right to develop OLX101A treatment globally. Based on the rights, the pharmaceutical company planned to speed up the ongoing conversation on licensee agreements with numerous global pharmaceutical and cosmetic companies.
The termination was due to a change in the internal policy of Hugel. The two companies agreed on returning the technology and license alike.
Therefore, Olix Pharmaceuticals becomes the only company with the exclusive right to develop OLX101A treatment globally. Based on the rights, the pharmaceutical company planned to speed up the ongoing conversation on licensee agreements with numerous global pharmaceutical and cosmetic companies.
광고를 불러오는 중...
![[NSPAD]삼성전자](https://file.nspna.com/ad/T01_samsung_gn_5138.gif "삼성전자[T01]")